Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
with histologically confirmed, 18 F-fluorodeoxyglucose ( 18 F-FDG)-PET
staged, recurrent or multiple primary NSCLC, suitable for SABR (
62 Gy, respectively (p=.037) (Fig.1). 5-years survival was 19.1% and 29.3% for
treatment with ≤ 62 Gy and > 62 Gy. Conclusion: RT dose may be an important
factor for outcome of patients with LA-NSCLC. Our analysis confirms the
importance of RT dose on outcome in patients with LA NSCLC, but since small
number of patients were included, no firm conclusion could be made and
further clinical investigation is warranted.
Keywords: Locally advanced NSCLC, dose of radiotherapy
POSTER SESSION 2 – P2.05: RADIOTHERAPY
CLINICAL OUTCOME –
TUESDAY, DECEMBER 6, 2016
P2.05-017 TUMOR REGRESSION GRADIENT PREDICTS DISEASE
FREE SURVIVAL
Patrick Berkovic 1 , Leen Paelinck 2 , Katrien Vandecasteele 2 , Akos Gulyban 1 ,
Carlos De Wagter 2 , Bruno Goddeeris 2 , Yolande Lievens 3
1 Liège University Hospital, Liege/Belgium, 2 Ghent University Hospital, Ghent/
Belgium, 3 Radiation Oncology Department, Ghent University Hospital, Ghent/
Belgium
Background: Tumor regression during chemoradiation (CRT) in stage III
non-small cell lung cancer patients has been described. Our aim was to
investigate whether the extent of the primary tumor shrinkage is associated
with local control and survival. Methods: Changes in the volume of the
primary tumor (GTV-T) of 41 patients treated with concurrent (cCRT) (n = 21) or
sequential (sCRT) (n=20) CRT were analyzed using cone-beam CT (CBCT) at
every fifth fraction (F5–F30). Only changes in the primary tumor (excluding
the lymph nodes) were considered. Previous research revealed F15 and F20 as
optimal timing for treatment adaptation for cCRT and sCRT respectively
(Berkovic et al. Acta Oncol 2015). Local control and survival data were
reviewed retrospectively. Impact of the tumor regression at the time of the
optimal adaptation timing during treatment (higher or lower than median)
and chemotherapy schedule (cCRT vs. sCRT) on local control and survival were
evaluated using the Kaplan-Meier survival comparison (log-rank test, p